Courtney D. DiNardo

The University of Texas MD Anderson Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

1.9Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy

Haematologica(2021)10.3324/haematol.2021.278762

Top 16%

1.3DataRank

Top 16%55 citations

Sarah L. King‐Smith, David Lawrence, Peer Arts, Jinghua Feng, James Andrews +38 more

Papers

Driven by 108 papers — median percentile 76. Top paper: “10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial”.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30210-6

N/A

6.4DataRank · unranked

334 citations

Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver +34 more

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

The Lancet Haematology(2021)10.1016/s2352-3026(21)00192-7

N/A

5.0DataRank · unranked

178 citations

Patrick K. Reville, Gautam Borthakur, Musa Yılmaz, Steven M. Kornblau, Yesid Alvarado +13 more

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

The Lancet Oncology(2021)10.1016/s1470-2045(21)00494-0

N/A

4.0DataRank · unranked

193 citations

Andre C. Schuh, Eytan M. Stein, Pau Montesinos, Andrew H. Wei, Stéphane de Botton +12 more

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

Cancer(2021)10.1002/cncr.33689

N/A

3.9DataRank · unranked

158 citations

Abhishek Maiti, Sanam Loghavi, Rasoul Pourebrahim, Tapan M. Kadia, Caitlin R. Rausch +14 more

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Advances(2021)10.1182/bloodadvances.2020003717

N/A

3.2DataRank · unranked

82 citations

Courtney D. DiNardo, Sa A. Wang, Jeffrey L. Jorgensen, Tapan M. Kadia, Naval Daver +28 more

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML

Journal of Clinical Oncology(2024)10.1200/jco.23.01911

N/A

2.7DataRank · unranked

152 citations

Naval Daver, Courtney D. DiNardo, Tapan M. Kadia, Lewis Nasr, Walid Macaron +19 more

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

Blood Cancer Journal(2022)10.1038/s41408-021-00604-2

N/A

2.5DataRank · unranked

95 citations

Koichi Takahashi, Naval Daver, Abhishek Maiti, Gautam Borthakur, Sanam Loghavi +14 more

RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax

Nature(2024)10.1038/s41586-024-08137-x

N/A

1.7DataRank · unranked

86 citations

Saul Carcamo, Maria Sirenko, Abhishek Maiti, Hager Mansour, Gulay Ulukaya +23 more

Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants

American Journal of Hematology(2023)10.1002/ajh.27070

N/A

1.6DataRank · unranked

48 citations

Sanam Loghavi, Yoheved Gerstein, Alexandre Bazinet, Koji Sasaki, Kelly S. Chien +19 more

Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia

American Journal of Hematology(2021)10.1002/ajh.26122

N/A

1.4DataRank · unranked

25 citations

Abhishek Maiti, Courtney D. DiNardo, Sanam Loghavi, Naval Daver, Tapan M. Kadia +11 more

The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy

Haematologica(2021)10.3324/haematol.2021.278762

Top 16%

1.3DataRank

Top 16%55 citations

Sarah L. King‐Smith, David Lawrence, Peer Arts, Jinghua Feng, James Andrews +38 more

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Journal of Hematology & Oncology(2023)10.1186/s13045-023-01476-8

N/A

1.3DataRank · unranked

51 citations

Muharrem Müftüoğlu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban‐Bravo +22 more

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Blood(2020)10.1182/blood.2019003988

N/A

0.969DataRank · unranked

638 citations

Ing Soo Tiong, Anna Quaglieri, Sarah MacRaild, Sanam Loghavi, Fiona C. Brown +24 more

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

Nature Cancer(2024)10.1038/s43018-024-00811-3

N/A

0.878DataRank · unranked

37 citations

Divij Verma, Natalia Baran, Tushar D. Bhagat, Anna Skwarska, Alessia Lodi +42 more

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Nature Communications(2021)10.1038/s41467-021-22874-x

N/A

0.717DataRank · unranked

118 citations

Kiyomi Morita, Courtney D. DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan +21 more

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements

Blood Cancer Journal(2021)10.1038/s41408-021-00557-6

N/A

0.692DataRank · unranked

100 citations

Jabra Zarka, Koji Sasaki, Wei Qiao, Daewoo Pak, Jing Ning +16 more

Clonal Evolution of Acute Myeloid Leukemia Revealed by High-Throughput Single-Cell Genomics

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.02.07.925743

N/A

0.633DataRank · unranked

67 citations

Feng Wang, Katharina Jahn, Jack Kuipers, Yuanqing Yan, Jairo Matthews +22 more

Association of unbalanced translocation der(1;7) with germline GATA2 mutations

Blood(2021)10.1182/blood.2021012781

Top 32%

0.626DataRank

Top 32%21 citations

Gudrun Göhring, Dennis D. Hickstein, Katherine R. Calvo, Courtney D. DiNardo, Michael Dworzak +42 more

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Leukemia(2020)10.1038/s41375-020-0778-0

N/A

0.596DataRank · unranked

52 citations

Srđan Verstovšek, Jörge E. Cortes, Susan Tse, Yvonne Gasior, Nitin Jain +19 more

Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis

Cancer(2021)10.1002/cncr.33814

N/A

0.593DataRank · unranked

51 citations

Courtney D. DiNardo, Wei Qiao, Tapan M. Kadia, Elias Jabbour, Caitlin R. Rausch +18 more

Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations

Blood(2024)10.1182/blood.2024025023

N/A

0.557DataRank · unranked

40 citations

Emma M. Groarke, Natthakan Thongon, Juan José Rodríguez‐Sevilla, Luiz Fernando Bazzo Catto, Marena R. Niewisch +37 more

Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41

Blood Advances(2023)10.1182/bloodadvances.2023010045

N/A

0.557DataRank · unranked

40 citations

Michael W. Drazer, Kai Yu, David Lawrence, Jinghua Feng, Luis Arriola‐Martinez +60 more

Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm

American Journal of Hematology(2021)10.1002/ajh.26417

N/A

0.546DataRank · unranked

37 citations

Marina Konopleva, Mrinal M. Patnaik, Elias Jabbour, Courtney D. DiNardo, Aref Al‐Kali +7 more

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

American Journal of Hematology(2022)10.1002/ajh.26451

N/A

0.483DataRank · unranked

24 citations

Koji Sasaki, Hagop M. Kantarjian, Naval Daver, Musa Yılmaz, Courtney D. DiNardo +13 more

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Blood Advances(2023)10.1182/bloodadvances.2022009632

N/A

0.483DataRank · unranked

24 citations

Faustine Ong, Farhad Ravandi, Graciela M. Nogueras‐González, Tapan M. Kadia, Naval Daver +15 more

Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes

Blood(2025)10.1182/blood.2024027244

N/A

0.465DataRank · unranked

13 citations

Bofei Wang, Jennifer Marvin‐Peek, Bin Yuan, Yu-Jen Kuo, Araceli Isabella Garza +17 more

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.10.27.357111

N/A

0.457DataRank · unranked

20 citations

Kiyomi Morita, Courtney D. DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan +21 more

Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation

American Journal of Hematology(2023)10.1002/ajh.26997

N/A

0.442DataRank · unranked

18 citations

Hagop M. Kantarjian, Naszrin Arani, Uday Popat, Álex Bataller, Koji Sasaki +19 more

Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML

Blood(2024)10.1182/blood.2024026388

N/A

0.395DataRank · unranked

10 citations

Christopher P. Mill, Prithviraj Bose, Lucia Masárová, Naveen Pemmaraju, Andrew Dunbar +18 more

Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7512

N/A

0.360DataRank · unranked

10 citations

Abhishek Maiti, Farhad Ravandi, Marina Konopleva, Yesid Alvarado, Tapan M. Kadia +14 more

Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept

Frontiers in Immunology(2023)10.3389/fimmu.2023.1249511

N/A

0.345DataRank · unranked

9 citations

Naval Daver, Myrna C. B. Godoy, Girish S. Shroff, Carol C. Wu, Luis F. Torre-Sada +19 more

Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7519

N/A

0.330DataRank · unranked

8 citations

Courtney D. DiNardo, Naveen Pemmaraju, Tapan M. Kadia, Caitlin R. Rausch, Kiran Naqvi +15 more

A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia

Blood Neoplasia(2025)10.1016/j.bneo.2025.100126

N/A

0.330DataRank · unranked

8 citations

Gabriel N. Mannis, Yazan F. Madanat, Brian A. Jonas, Neil Dunavin, Gail J. Roboz +15 more

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses

Research Square(2023)10.21203/rs.3.rs-2518774/v1

N/A

0.312DataRank · unranked

7 citations

Courtney D. DiNardo, Tushar D. Bhagat, Natalia Baran, Alessia Lodi, Kapil Saxena +38 more

Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1973675

N/A

0.308DataRank · unranked

5 citations

Abhishek Maiti, Courtney D. DiNardo, Wei Qiao, Jing Ning, Sanam Loghavi +13 more

Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM)

Blood Cancer Journal(2024)10.1038/s41408-024-00981-4

N/A

0.287DataRank · unranked

4 citations

Warren Fiskus, Courtney D. DiNardo, Patrick K. Reville, John A. Davis, Christine Birdwell +10 more

Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase

Blood Advances(2025)10.1182/bloodadvances.2025016898

N/A

0.262DataRank · unranked

4 citations

Lucia Masárová, Christopher P. Mill, Christine Birdwell, Kaberi Das, Hanxi Hou +16 more

Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies

American Journal of Hematology(2025)10.1002/ajh.70046

N/A

0.245DataRank · unranked

4 citations

Sanam Loghavi, Alexandre Bazinet, Álex Bataller, Ian Bouligny, Naval Daver +15 more

PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML

Blood Neoplasia(2025)10.1016/j.bneo.2025.100121

N/A

0.241DataRank · unranked

4 citations

Tatsuro Watanabe, Kaori Saito, Abdullah Khasawneh, Abhishek Maiti, Zhihong Zeng +10 more

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome

Haematologica(2025)10.3324/haematol.2024.286559

N/A

0.165DataRank · unranked

2 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado +19 more

Risk of early death after acute leukemia diagnosis among adolescents and young adults

JNCI Cancer Spectrum(2025)10.1093/jncics/pkaf065

N/A

0.165DataRank · unranked

2 citations

Clark R. Andersen, Vidya Puthenpura, Nicholas J. Short, Kelly W. Merriman, Mahesh Swaminathan +14 more

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blood(2024)10.1182/blood-2024-203938

N/A

0.104DataRank · unranked

1 citations

Hagop M. Kantarjian, Musa Yılmaz, Naval Daver, Gautam Borthakur, Courtney D. DiNardo +15 more

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Blood(2024)10.1182/blood-2024-207413

N/A

0.104DataRank · unranked

1 citations

Jennifer Marvin‐Peek, Marina Konopleva, Gautam Borthakur, Naval Daver, Hussein A. Abbas +21 more

Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1

Blood Neoplasia(2025)10.1016/j.bneo.2025.100145

N/A

0.104DataRank · unranked

1 citations

Wei‐Ying Jen, Guillermo Montalban‐Bravo, Xuemei Wang, Sanam Loghavi, Sravanthi Lavu +15 more

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial

Cancer(2025)10.1002/cncr.35840

N/A

0.104DataRank · unranked

1 citations

Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Elias Jabbour +13 more

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

Leukemia(2022)10.1038/s41375-022-01707-w

N/A

0DataRank · unranked

82 citations

Naval Daver, Steffen Boettcher, Christopher P. Mill, Koji Sasaki, Christine Birdwell +11 more

Assessing patient attitudes toward genetic testing for hereditary hematologic malignancy

European Journal Of Haematology(2022)10.1111/ejh.13880

N/A

0DataRank · unranked

1 citations

Sarah A. Bannon, Laura S. Farach, Samuel M. Hyde, S. Shahrukh Hashmi, Chelsea Wagner +2 more

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

Blood Advances(2022)10.1182/bloodadvances.2021006689

N/A

0DataRank · unranked

1 citations

Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Naveen Pemmaraju, Nicholas J. Short +6 more

Phase II study of lower-intensity frontline therapy for newly diagnosed patients with AML who are unfit or otherwise not eligible for frontline clinical trials.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e19028

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Naveen Pemmaraju, Guillermo Montalban‐Bravo, Kelly S. Chien, Naval Daver +12 more

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1

Blood Cancer Journal(2023)10.1038/s41408-023-00826-6

N/A

0DataRank · unranked

55 citations

Christopher P. Mill, Christine Birdwell, John A. Davis, Kaberi Das, Steffen Boettcher +13 more

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms

Blood(2022)10.1182/blood.2021014956

N/A

0DataRank · unranked

140 citations

Veronica Guerra, James A. Kennedy, Yuanqing Yan, Joanne I. Hsu, Feng Wang +20 more

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

Signal Transduction and Targeted Therapy(2022)10.1038/s41392-021-00870-3

N/A

0DataRank · unranked

186 citations

Bridget Riley‐Gillis, Lina Han, Yannan Jia, Alessia Lodi, Haijiao Zhang +36 more

Contemporary outcomes for adults with AML requiring ICU admission.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7025

N/A

0DataRank · unranked

4 citations

Koji Sasaki, Alexis Geppner, Fadi Haddad, Shehab Mohamed, Daniel Rivera +15 more

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience

Cancers(2023)10.3390/cancers15071983

N/A

0DataRank · unranked

33 citations

Amber Gibson, Jiasen He, David McCall, Michael Roth, César Núnêz +23 more

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Blood Advances(2023)10.1182/bloodadvances.2022009391

N/A

0DataRank · unranked

29 citations

Tapan M. Kadia, Nicholas J. Short, Gautam Borthakur, Sa A. Wang, Wei Wang +22 more

Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Nature Communications(2021)10.1038/s41467-021-23280-z

N/A

0DataRank · unranked

7 citations

Feng Wang, Katharina Jahn, Tianyuan Hu, Tomoyuki Tanaka, Yuya Sasaki +28 more

Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1429

N/A

0DataRank · unranked

23 citations

Warren Fiskus, Naval Daver, Nathaniel R. Wilson, Farhad Ravandi, Guillermo Garcia‐Manero +19 more

Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation

Cancer(2023)10.1002/cncr.34728

N/A

0DataRank · unranked

20 citations

Hagop M. Kantarjian, Nicholas J. Short, Wei Qiao, Jing Ning, Branko Cuglievan +12 more

Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission

Cancer(2021)10.1002/cncr.33409

N/A

0DataRank · unranked

10 citations

Hagop M. Kantarjian, Farhad Ravandi, Naval Daver, Xuemei Wang, Elias Jabbour +16 more

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression

Leukemia(2023)10.1038/s41375-023-02108-3

N/A

0DataRank · unranked

11 citations

Warren Fiskus, Tapan M. Kadia, Christopher P. Mill, Koji Sasaki, Naval Daver +13 more

Association between bariatric surgery and outcomes in chronic myeloid leukemia

Cancer(2023)10.1002/cncr.34725

N/A

0DataRank · unranked

11 citations

Hagop M. Kantarjian, Aram Bidikian, Elias Jabbour, Nicholas J. Short, Jing Ning +10 more

Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets

Expert Opinion on Investigational Drugs(2023)10.1080/13543784.2023.2179482

N/A

0DataRank · unranked

10 citations

Margarita Ríos, John Ye, Adan Rios, Cheng Cheng Zhang, Naval Daver +4 more

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1

Leukemia(2023)10.1038/s41375-023-01882-4

N/A

0DataRank · unranked

10 citations

Warren Fiskus, Kaberi Das, John A. Davis, Christine Birdwell, Tapan M. Kadia +11 more

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

Leukemia(2021)10.1038/s41375-021-01240-2

N/A

0DataRank · unranked

31 citations

Danielle Hammond, Courtney D. DiNardo, Marina Konopleva, Gautam Borthakur, Nicholas J. Short +15 more

Cigarette smoke exposure accelerates AML progression in FLT3-ITD models

Blood Advances(2023)10.1182/bloodadvances.2023010111

N/A

0DataRank · unranked

2 citations

Huaxian Ma, Mansour Alfayez, Daniel E. Morales-Mantilla, Fei Wang, Yue Lu +10 more

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia

Haematologica(2021)10.3324/haematol.2021.278369

N/A

0DataRank · unranked

32 citations

Huaxian Ma, Prerna Malaney, Xiaorui Zhang, Marisa J.L. Aitken, Po Yee Mak +12 more

Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms

Blood(2023)10.1182/blood-2023-190400

N/A

0DataRank · unranked

1 citations

Zongrui Li, Abhishek Maiti, Tomoyuki Tanaka, Hidetaka Uryu, Ken Furudate +21 more

Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Blood(2023)10.1182/blood-2023-182841

N/A

0DataRank · unranked

0 citations

Alexandre Bazinet, Courtney D. DiNardo, Gautam Borthakur, Nicholas J. Short, Elias Jabbour +12 more

Hematopoiesis under telomere attrition at the single-cell resolution

Nature Communications(2021)10.1038/s41467-021-27206-7

N/A

0DataRank · unranked

36 citations

Feiyang Ma, Andrea Santoni, Matteo Marchesini, Elena Fiorini, Ashley Rose +20 more

Impact of frontline treatment approach on outcomes of myeloid blast phase CML

Journal of Hematology & Oncology(2021)10.1186/s13045-021-01106-1

N/A

0DataRank · unranked

37 citations

Elias Jabbour, Ghayas C. Issa, Koji Sasaki, Farhad Ravandi, Abhishek Maiti +11 more

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Blood(2024)10.1182/blood.2023022832

N/A

0DataRank · unranked

42 citations

Jessica Piel, Michael P. Collins, Murphy Hentemann, Branko Cuglievan, Christopher P. Mill +21 more

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia

Blood(2021)10.1182/blood.2020010483

N/A

0DataRank · unranked

43 citations

Kiyomi Morita, Sanam Loghavi, Feng Wang, Ken Furudate, Yuya Sasaki +19 more

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Blood Cancer Journal(2021)10.1038/s41408-021-00453-z

N/A

0DataRank · unranked

45 citations

Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Courtney D. DiNardo, Naval Daver +12 more

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Blood Advances(2021)10.1182/bloodadvances.2020003934

N/A

0DataRank · unranked

48 citations

Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Naval Daver, Tapan M. Kadia +7 more

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Blood Cancer Journal(2021)10.1038/s41408-021-00410-w

N/A

0DataRank · unranked

126 citations

Courtney D. DiNardo, Naval Daver, Caitlin R. Rausch, Farhad Ravandi, Tapan M. Kadia +20 more

Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study

Leukemia Research(2024)10.1016/j.leukres.2024.107597

N/A

0DataRank · unranked

1 citations

Eduardo Yepez Guevara, Courtney D. DiNardo, Elias Jabbour, Issa Ghayas, Ravin Ratan +3 more

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Blood(2024)10.1182/blood-2024-203706

N/A

0DataRank · unranked

5 citations

Jayastu Senapati, Sanam Loghavi, Patrick K. Reville, Bofei Wang, Tapan M. Kadia +21 more

Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up

Blood(2024)10.1182/blood-2024-211599

N/A

0DataRank · unranked

3 citations

H. Kantarjian, Edward Ayoub, Akhil Jain, Tapan M. Kadia, Courtney D. DiNardo +13 more

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood(2024)10.1182/blood-2024-211110

N/A

0DataRank · unranked

2 citations

Philip A. Thompson, Jan A. Burger, Musa Yılmaz, Nitin B. Jain, Tapan M. Kadia +23 more

Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Blood(2024)10.1182/blood-2024-209558

N/A

0DataRank · unranked

2 citations

Wei‐Ying Jen, Courtney D. DiNardo, Kelly S. Chien, Danielle Hammond, Yesid Alvarado Valero +12 more

Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia

Blood(2024)10.1182/blood-2024-208890

N/A

0DataRank · unranked

1 citations

Kelly S. Chien, Sanam Loghavi, Rashmi Kanagal‐Shamanna, Anuya Natu, Mark E. Gurney +22 more

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm

Blood Cancer Journal(2021)10.1038/s41408-021-00497-1

N/A

0DataRank · unranked

191 citations

Courtney D. DiNardo, Ghayas C. Issa

Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy‐Based Regimens

American Journal of Hematology(2025)10.1002/ajh.70048

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Nicholas J. Short, Nitin Jain, Ghayas C. Issa, Himachandana Atluri +9 more

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Blood(2024)10.1182/blood-2024-210779

N/A

0DataRank · unranked

0 citations

Hussein A. Abbas, Guillermo Garcia‐Manero, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo +19 more

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Blood(2024)10.1182/blood-2024-205186

N/A

0DataRank · unranked

0 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado Valero +15 more

Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant

Blood(2024)10.1182/blood-2024-208106

N/A

0DataRank · unranked

0 citations

Koichi Saeki, Hiroshi Haeno, Chiraag D. Kapadia, Ken Furudate, Jyoti Nangalia +35 more

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Blood(2024)10.1182/blood-2024-202414

N/A

0DataRank · unranked

0 citations

H. Kantarjian, Wei‐Ying Jen, Gautam Borthakur, Naval Daver, Abhishek Maiti +14 more

Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0229

N/A

0DataRank · unranked

15 citations

Jayastu Senapati, Hagop M. Kantarjian, Bofei Wang, Patrick K. Reville, Sanam Loghavi +21 more

Clinical value of event-free survival in acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2019001150

N/A

0DataRank · unranked

7 citations

Hagop M. Kantarjian, Vinita Popat, Gautam Borthakur, Guillermo Garcia‐Manero, Marina Konopleva +16 more

Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia

Nature Reviews Clinical Oncology(2025)10.1038/s41571-025-01068-0

N/A

0DataRank · unranked

12 citations

Ellen Weisberg, Hiu Yan Lam, Donavan J. J. Tan, Andrew J. Innes, Yubin Ge +17 more

A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3790

N/A

0DataRank · unranked

11 citations

Amir T. Fathi, Ashwin Kishtagari, Kapil N. Bhalla, Alfonso Quintás‐Cardama, Sarah A. Reilly +25 more

Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation

Nature Genetics(2025)10.1038/s41588-025-02235-w

N/A

0DataRank · unranked

11 citations

Koichi Saeki, Hiroshi Haeno, Chiraag D. Kapadia, Ken Furudate, Jyoti Nangalia +39 more

Germline DNMT3A mutation in familial acute myeloid leukaemia

Epigenetics(2020)10.1080/15592294.2020.1809871

N/A

0DataRank · unranked

10 citations

Hannah C. Beird, Marcos R. Estecio, Swanand Hardikar, Koichi Takahashi, Sarah A. Bannon +12 more

Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors

Blood(2020)10.1182/blood.2019002922

N/A

0DataRank · unranked

73 citations

Warren Fiskus, Christopher P. Mill, Dimuthu Perera, Taghi Manshouri, Bernardo H Lara +18 more

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

American Journal of Hematology(2020)10.1002/ajh.26061

N/A

0DataRank · unranked

103 citations

Wei Qiao, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Elias Jabbour +26 more

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Nature Communications(2020)10.1038/s41467-020-19119-8

N/A

0DataRank · unranked

391 citations

Feng Wang, Katharina Jahn, Tianyuan Hu, Tomoyuki Tanaka, Yuya Sasaki +28 more

MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia

British Journal of Haematology(2025)10.1111/bjh.70171

N/A

0DataRank · unranked

3 citations

Guojun Tang, Eitan Kugler, Jennifer Croden, Koji Sasaki, Alexandre Bazinet +20 more

BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML

Leukemia(2025)10.1038/s41375-025-02842-w

N/A

0DataRank · unranked

2 citations

Warren Fiskus, Christopher P. Mill, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo +13 more

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Haematologica(2020)10.3324/haematol.2020.252569

N/A

0DataRank · unranked

174 citations

Caitlin R. Rausch, Jörge E. Cortes, Naveen Pemmaraju, Naval Daver, Farhad Ravandi +30 more

Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor

Haematologica(2025)10.3324/haematol.2025.288553

N/A

0DataRank · unranked

2 citations

Sanam Loghavi, Musa Yılmaz, Omer Karrar, Kunhwa Kim, Courtney D. DiNardo +15 more

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial

Blood Cancer Journal(2025)10.1038/s41408-025-01265-1

N/A

0DataRank · unranked

1 citations

Courtney D. DiNardo, Abhishek Maiti, Naveen Pemmaraju, Maro Ohanian, Naval Daver +19 more

1250MO Outcomes of patients with chronic myeloid leukemia receiving second-line therapy

Annals of Oncology(2025)10.1016/j.annonc.2025.08.1884

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Sara Dellasala, G. Issa, Tapan Kadia, J. Senapati +10 more

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2020003120

N/A

0DataRank · unranked

182 citations

Guillermo Montalban‐Bravo, Hyunsoo Hwang, Jing Ning, Miguel Franquiz, Rashmi Kanagal‐Shamanna +12 more

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations

Blood Cancer Journal(2025)10.1038/s41408-025-01251-7

N/A

0DataRank · unranked

1 citations

Christopher P. Mill, Jessica Piel, Mike Collins, Murphy Hentemann, Branko Cuglievan +18 more

Development and validation of the predictive aplastic score system (PASS): A simplified tool to diagnose acquired aplastic anemia in adults

Leukemia(2025)10.1038/s41375-026-02924-3

N/A

0DataRank · unranked

0 citations

HeeJin Cheon, Jiayin Zheng, Stephanie Soewito, Jimmy Lee, Neha Kalakuntla +10 more

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Blood Advances(2022)10.1182/bloodadvances.2022008316

N/A

0DataRank · unranked

56 citations

Aram Bidikian, Sangeetha Venugopal, Marina Konopleva, Courtney D. DiNardo, Tapan M. Kadia +20 more

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Journal of Hematology & Oncology(2022)10.1186/s13045-022-01229-z

N/A

0DataRank · unranked

32 citations

Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron +18 more

Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis

Cancer Epidemiology Biomarkers & Prevention(2022)10.1158/1055-9965.epi-21-1388

N/A

0DataRank · unranked

30 citations

Clark R. Andersen, Branko Cuglievan, David McCall, Philip J. Lupo, Susan K. Parsons +7 more

Courtney D. DiNardo

Indexed papers

Top data-sharing exemplar

Papers